Robert W. Baird Cuts Fortrea (NASDAQ:FTRE) Price Target to $16.00

Fortrea (NASDAQ:FTRE) had its target price decreased by Robert W. Baird from $19.00 to $16.00 in a research note released on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other brokerages have also recently commented on FTRE. Evercore set a $25.00 target price on shares of Fortrea and gave the company an “outperform” rating in a report on Tuesday, January 6th. TD Cowen increased their price objective on Fortrea from $7.00 to $15.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Barclays set a $15.00 target price on Fortrea and gave the company an “equal weight” rating in a research note on Monday, December 15th. Wedbush set a $21.00 price target on Fortrea in a research note on Thursday, December 11th. Finally, Truist Financial set a $22.00 price target on Fortrea and gave the stock a “buy” rating in a report on Thursday, January 8th. Four investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Fortrea presently has an average rating of “Hold” and an average target price of $16.15.

Fortrea Price Performance

FTRE stock opened at $10.72 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $1.00 billion, a P/E ratio of -0.98, a PEG ratio of 0.34 and a beta of 1.81. The business has a 50 day simple moving average of $15.14 and a 200-day simple moving average of $12.37. Fortrea has a twelve month low of $3.97 and a twelve month high of $18.67.

Fortrea (NASDAQ:FTRE) last announced its earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.07). The business had revenue of $660.50 million during the quarter, compared to analyst estimates of $665.22 million. Fortrea had a negative net margin of 36.21% and a positive return on equity of 6.23%. As a group, equities analysts anticipate that Fortrea will post 0.51 EPS for the current year.

Institutional Investors Weigh In On Fortrea

A number of hedge funds and other institutional investors have recently bought and sold shares of FTRE. Royal Bank of Canada boosted its position in shares of Fortrea by 48.9% during the 1st quarter. Royal Bank of Canada now owns 121,707 shares of the company’s stock worth $920,000 after purchasing an additional 39,944 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Fortrea in the first quarter valued at about $196,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Fortrea by 10.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 282,780 shares of the company’s stock worth $2,135,000 after buying an additional 27,746 shares in the last quarter. Focus Partners Wealth purchased a new stake in Fortrea during the first quarter worth about $80,000. Finally, Acadian Asset Management LLC acquired a new position in Fortrea during the first quarter worth about $65,000.

Fortrea News Roundup

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said full‑year revenue and adjusted EBITDA delivered in line with targets and that full‑year cost savings exceeded prior targets — a reassurance on operational execution. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
• Positive Sentiment: Robert W. Baird kept an “outperform” rating and a $16 price target (implying ~49% upside vs. current levels), signaling some analysts remain bullish on the company’s longer‑term outlook. Baird price target note
• Neutral Sentiment: Several full transcripts and earnings‑call highlights were published (useful for parsing management commentary and client/contract trends), giving investors primary‑source detail on drivers and margin dynamics. Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage remains active — a recent Benzinga roundup reviews seven ratings, which can amplify volatility as differing views are disseminated. Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
• Negative Sentiment: Q4 results missed consensus: reported EPS $0.09 vs. $0.16 expected, and revenue $660.5M vs. ~$665M expected — the headline misses are driving the immediate negative reaction. Fortrea Q4 Earnings and Revenues Lag Estimates (Zacks)
• Negative Sentiment: Barclays cut its price target to $12 and set an “equal weight” rating — a formal shift toward neutrality/less bullishness that can pressure sentiment and weaken near‑term buyer conviction. Barclays price target cut
• Negative Sentiment: FY‑2026 revenue guidance was given in a range (~$2.6B–$2.7B), which sits slightly below consensus at the top end — the cautious top‑line outlook and an unclear EPS guide left some investors wanting more upside visibility. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

About Fortrea

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.